United Arab Emirates (UAE) Biosimilars Market (2024-2030) Outlook | Analysis, Companies, Forecast, Value, Share, Trends, Industry, Revenue, Growth & Size

Market Forecast By Product (Insulin, Follitropin, Calcitonin, Glucagon, Teriparatide, Others), By Indication (Oncology, Offsite Treatment, Chronic Disorders, Blood Disorders, Infectious Diseases, Others), By Manufacturing (Outsourced, In-house) And Competitive Landscape
Product Code: ETC069959 Publication Date: Aug 2023 Updated Date: Jan 2024 Product Type: Report
Publisher: 6Wresearch No. of Pages: 70 No. of Figures: 35 No. of Tables: 5

United Arab Emirates (UAE) Biosimilars Market Synopsis

The United Arab Emirates (UAE) biosimilars market has been witnessing steady growth, driven by the increasing demand for cost-effective and high-quality biologic medicines. Biosimilars are biological products that are highly similar to approved reference biologics, offering a more affordable alternative for patients and healthcare systems. In the UAE, as the government focuses on expanding access to healthcare and reducing healthcare expenditure, the adoption of biosimilars has gained traction. The market`s growth is influenced by the UAE robust regulatory framework for biosimilars, the prevalence of chronic diseases, and the impact of the Covid-19 pandemic on healthcare systems.

Drivers of the Market

The growth of the UAE biosimilars market is propelled by several key drivers. Firstly, the rising burden of chronic diseases, such as cancer, autoimmune disorders, and diabetes, has increased the demand for biologic therapies. Biosimilars offer cost-effective treatment options, allowing a broader population to access these life-saving medications. Secondly, the UAE government`s initiatives to promote healthcare sustainability and cost containment have led to the inclusion of biosimilars in national formularies and treatment guidelines, encouraging their adoption in healthcare facilities.

Challenges of the Market

Despite the positive market outlook, the UAE biosimilars market faces certain challenges. One significant challenge is the complexity of biosimilar development and regulatory approval. Manufacturers must demonstrate a high degree of similarity and comparability to reference biologics through extensive clinical studies, which can be resource-intensive and time-consuming. Additionally, ensuring patient and physician confidence in biosimilars` safety and efficacy is crucial to drive their acceptance and adoption.

Covid-19 Impact on the Market

The Covid-19 pandemic, which emerged in 2020, had a notable impact on the UAE biosimilars market. The pandemic put immense pressure on healthcare systems, leading to a heightened focus on cost-saving strategies and the need for affordable treatment options. Biosimilars, as cost-effective alternatives to reference biologics, became a key consideration for healthcare providers and policymakers to manage the increased demand for healthcare services during the pandemic.

Key Players of the Market

The UAE biosimilars market is experiencing robust growth, driven by an increasing focus on cost-effective healthcare solutions and the rising demand for biologic drugs. As governments and healthcare providers strive to improve accessibility to advanced treatments, biosimilars offer a compelling option for patients and healthcare systems. Key players leading this thriving market include pharmaceutical giants such as Sandoz International GmbH (a subsidiary of Novartis), Pfizer Inc., and Amgen Inc. These industry leaders are actively investing in research and development to develop high-quality biosimilars that meet stringent regulatory standards, providing safe and affordable alternatives to expensive biologics. Additionally, local players like Julphar Gulf Pharmaceutical Industries and Neopharma are making significant contributions to the market`s growth, reinforcing the country`s position as a hub for biosimilar production and distribution. As the UAE continues to expand its biosimilar portfolio and promote their adoption, the biosimilars market is set to witness further advancements, delivering enhanced healthcare outcomes and cost savings for patients and healthcare stakeholders.

Key Highlights of the Report:

  • United Arab Emirates (UAE) Biosimilars Market Outlook
  • Market Size of United Arab Emirates (UAE) Biosimilars Market, 2020
  • Forecast of United Arab Emirates (UAE) Biosimilars Market, 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Revenues & Volume for the Period 2023 - 2027
  • United Arab Emirates (UAE) Biosimilars Market Trend Evolution
  • United Arab Emirates (UAE) Biosimilars Market Drivers and Challenges
  • United Arab Emirates (UAE) Biosimilars Price Trends
  • United Arab Emirates (UAE) Biosimilars Porter's Five Forces
  • United Arab Emirates (UAE) Biosimilars Industry Life Cycle
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Product for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Insulin for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Follitropin for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Calcitonin for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Glucagon for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Teriparatide for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Others for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Indication for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Oncology for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Offsite Treatment for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Chronic Disorders for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Blood Disorders for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Infectious Diseases for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Others for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Manufacturing for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By Outsourced for the Period 2023 - 2027
  • Historical Data and Forecast of United Arab Emirates (UAE) Biosimilars Market Revenues & Volume By In-house for the Period 2023 - 2027
  • United Arab Emirates (UAE) Biosimilars Import Export Trade Statistics
  • Market Opportunity Assessment By Product
  • Market Opportunity Assessment By Indication
  • Market Opportunity Assessment By Manufacturing
  • United Arab Emirates (UAE) Biosimilars Top Companies Market Share
  • United Arab Emirates (UAE) Biosimilars Competitive Benchmarking By Technical and Operational Parameters
  • United Arab Emirates (UAE) Biosimilars Company Profiles
  • United Arab Emirates (UAE) Biosimilars Key Strategic Recommendations
Frequently Asked Questions About the Market Study (FAQs):
6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.
Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

1 Executive Summary

2 Introduction

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3 United Arab Emirates (UAE) Biosimilars Market Overview

3.1 United Arab Emirates (UAE) Country Macro Economic Indicators

3.2 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, 2020 & 2027F

3.3 United Arab Emirates (UAE) Biosimilars Market - Industry Life Cycle

3.4 United Arab Emirates (UAE) Biosimilars Market - Porter's Five Forces

3.5 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume Share, By Product, 2020 & 2027F

3.6 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume Share, By Indication, 2020 & 2027F

3.7 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume Share, By Manufacturing, 2020 & 2027F

4 United Arab Emirates (UAE) Biosimilars Market Dynamics

4.1 Impact Analysis

4.2 Market Drivers

4.3 Market Restraints

5 United Arab Emirates (UAE) Biosimilars Market Trends

6 United Arab Emirates (UAE) Biosimilars Market, By Types

6.1 United Arab Emirates (UAE) Biosimilars Market, By Product

6.1.1 Overview and Analysis

6.1.2 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Product, 2018 - 2027F

6.1.3 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Insulin, 2018 - 2027F

6.1.4 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Follitropin, 2018 - 2027F

6.1.5 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Calcitonin, 2018 - 2027F

6.1.6 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Glucagon, 2018 - 2027F

6.1.7 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Teriparatide, 2018 - 2027F

6.1.8 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F

6.2 United Arab Emirates (UAE) Biosimilars Market, By Indication

6.2.1 Overview and Analysis

6.2.2 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Oncology, 2018 - 2027F

6.2.3 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Offsite Treatment, 2018 - 2027F

6.2.4 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Chronic Disorders, 2018 - 2027F

6.2.5 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Blood Disorders, 2018 - 2027F

6.2.6 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Infectious Diseases, 2018 - 2027F

6.2.7 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Others, 2018 - 2027F

6.3 United Arab Emirates (UAE) Biosimilars Market, By Manufacturing

6.3.1 Overview and Analysis

6.3.2 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By Outsourced, 2018 - 2027F

6.3.3 United Arab Emirates (UAE) Biosimilars Market Revenues & Volume, By In-house, 2018 - 2027F

7 United Arab Emirates (UAE) Biosimilars Market Import-Export Trade Statistics

7.1 United Arab Emirates (UAE) Biosimilars Market Export to Major Countries

7.2 United Arab Emirates (UAE) Biosimilars Market Imports from Major Countries

8 United Arab Emirates (UAE) Biosimilars Market Key Performance Indicators

9 United Arab Emirates (UAE) Biosimilars Market - Opportunity Assessment

9.1 United Arab Emirates (UAE) Biosimilars Market Opportunity Assessment, By Product, 2020 & 2027F

9.2 United Arab Emirates (UAE) Biosimilars Market Opportunity Assessment, By Indication, 2020 & 2027F

9.3 United Arab Emirates (UAE) Biosimilars Market Opportunity Assessment, By Manufacturing, 2020 & 2027F

10 United Arab Emirates (UAE) Biosimilars Market - Competitive Landscape

10.1 United Arab Emirates (UAE) Biosimilars Market Revenue Share, By Companies, 2020

10.2 United Arab Emirates (UAE) Biosimilars Market Competitive Benchmarking, By Operating and Technical Parameters

11 Company Profiles

12 Recommendations

13 Disclaimer

Pricing
  • Single User License
    $ 1,995
  • Department License
    $ 2,400
  • Site License
    $ 3,120
  • Global License
    $ 3,795
6Wresearch Support

Any Query

Call: +91-11-4302-4305
Email us: sales@6wresearch.com
Any Query? Click Here

Industry Events and Analyst Meet

Our Clients

Airtel
Canon
Contec
HoneyWell
Kriloskar
Pwc Logo
Samsung
Tata Teleservices

Whitepaper

Read All